{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cervia C"],"funding":["Schweizerische Akademie der Medizinischen Wissenschaften","Swiss National Science Foundation","Gottfried und Julia Bangerter-Rhyner-Stiftung (Bangerter-Stiftung)","Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)","University of Zurich (UZH Forschungskredit Candoc","Gottfried und Julia Bangerter-Rhyner-Stiftung","Clinical Research Priority Program CYTIMM-Z of University of Zurich (UZH), Pandemic Fund of University of Zurich (UZH), Innovation grant of University Hospital Zurich"],"pagination":["446"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8789854"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals w"],"journal":["Nature communications"],"pubmed_title":["Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome."],"pmcid":["PMC8789854"],"funding_grant_id":["323530-177975","310030-200669","YTCR 32/18","NRP 78 Implementation Programme","323530-191220","323530-191230","4078P0-198431"],"pubmed_authors":["Rudiger A","Menges D","Bachli E","Nilsson J","Zurbuchen Y","Taeschler P","Raeber ME","Adamo S","Held U","Boyman O","Huber LC","Puhan MA","Cervia C","Hasler S","Stussi-Helbling M","Ballouz T"],"additional_accession":[]},"is_claimable":false,"name":"Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.","description":"Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals w","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T14:59:05.409Z","creation":"2025-04-04T14:59:05.409Z"},"accession":"S-EPMC8789854","cross_references":{"pubmed":["35078982"],"doi":["10.1038/s41467-021-27797-1"]}}